Effects of NMDA-Receptor Antagonist Treatment on c-fos Expression in Rat Brain Areas Implicated in Schizophrenia

被引：0
作者：
Jussi Väisänen
Jouni Ihalainen
Heikki Tanila
Eero Castrén
机构：
[1] University of Kuopio,A.I. Virtanen Institute
[2] University of Kuopio,Department of Psychiatry
[3] University of Kuopio,Department of Neuroscience and Neurology
[4] University of Helsinki,Neuroscience Center
来源：
Cellular and Molecular Neurobiology | 2004年 / 24卷
关键词：
schizophrenia; MK801; neural circuits; NMDA;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
1. The noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonists produce behavioral responses that closely resemble both positive and negative symptoms of schizophrenia. These drugs also induce excitatory and neurotoxic effects in limbic cortical areas.
引用
收藏
页码：769 / 780
页数：11
相关论文
共 109 条
[1]  
Andreasen N. C.(1999)A unitary model of schizophrenia---Bleuler’s ‘‘fragmented phrene’’ as schizencephaly. Arch. Gen. Psychiatry 56 781-787
[2]  
Braff D. L.(1999)Connecting the ‘‘dots’’ of brain dysfunction in schizophrenia. Arch. Gen. Psychiatry 56 791-793
[3]  
Castrén E.(1993)Differential effects of MK-801 on the brain-derived neurotrophic factor mRNA levels in different regions of rat brain. Exp. Neurol. 122 244-252
[4]  
Berzaghi M. P.(2002)Distinct pattern of Neuroscience 115 67-78
[5]  
Lindholm D.(1990) mRNA expression after systematic and intra-accumbens amphetamine and MK-801. Neurosci. Lett. 113 144-150
[6]  
Thoenen H.(1995)MK-801 induces Biol Psychiatry 38 788-796
[7]  
DeLeonibus E.(1993) protein in thalamic and neocortical neurons of rat brain. Biol. Psychiatry 34 119-121
[8]  
Mele A.(1993)Age-specific neurotoxicity in the rat associated with NMDA receptor blockade: Potential relevance to schizophrenia? Neuroscience 53 749-758
[9]  
Oliverio A.(2001)Antipsychotic drugs block phencyclidine receptor-mediated neurotoxicity. Am. J. Med. Genet. 105 50-52
[10]  
Pert A.(1995)Induction and suppression of immediate early genes in specific rat brain regions by the non-competitive N-methyl- Pharmacol. Rev. 47 134-178
12345678910